APGE250516P60000
- 0.00
- 0.000.00%
Apogee Therapeutics Newsroom
Wall Street Analysts Believe Apogee Therapeutics Inc. (APGE) Could Rally 134%: Here's Is How to Trade
Apogee Therapeutics to Participate at the Bank of America 2025 Health Care Conference
Wall Street Set to Open Mixed Thursday; Durable Goods Orders, Jobless Claims Rise
Companies Like Apogee Therapeutics (NASDAQ:APGE) Are In A Position To Invest In Growth
One Apogee Therapeutics Insider Raised Their Stake In The Previous Year
BofA Securities Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Cuts Target Price to $78
Express News | Apogee Therapeutics Inc : Jefferies Raises Target Price to $88 From $86
Is Apogee Therapeutics (APGE) Among the Best IPO Stocks to Buy in 2025?
12 Health Care Stocks Moving In Thursday's After-Market Session
Citi Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $95
Apogee Therapeutics Analyst Ratings
Citigroup Initiates Apogee Therapeutics at Buy With $95 Price Target
Express News | Apogee Therapeutics Inc - MSA to Terminate in February 2035
Express News | Apogee Therapeutics Inc - Enters Master Services Agreement With Samsung Biologics
TD Cowen Maintains Apogee Therapeutics(APGE.US) With Buy Rating
BofA Securities Initiates Apogee Therapeutics(APGE.US) With Buy Rating, Announces Target Price $80
CCORF Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $89
Optimistic Buy Rating for Apogee Therapeutics Driven by Promising Clinical Trial Developments
Atopic Dermatitis: 2025 Pipeline Insights Report Covering 100+ Companies and 120+ Pipeline Drugs, Including ICP-332 (Innocare Pharma), APG777 (Apogee Therapeutics), and Barzolvolimab (Celldex Therapeutics)
Jefferies Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $86